{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:01:26Z","timestamp":1791313286399,"version":"4.3.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ijantimicag.2013.05.018","type":"journal-article","created":{"date-parts":[[2013,7,20]],"date-time":"2013-07-20T09:00:18Z","timestamp":1374310818000},"page":"289-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review"],"prefix":"10.1016","volume":"42","author":[{"given":"Suzanne","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Koulenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10096-009-0833-2","article-title":"Fosfomycin: an old, new friend?","volume":"29","author":"Popovic","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0010","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ijantimicag.2009.08.013","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections","volume":"34","author":"Roussos","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1469-0691.2011.03636.x","article-title":"Fosfomycin: an old\u2013new antibiotic","volume":"18","author":"Raz","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0020","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1128\/AAC.44.10.2728-2732.2000","article-title":"Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues","volume":"44","author":"Frossard","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijantimicag.2010.09.002","article-title":"Adverse events associated with intravenous fosfomycin","volume":"37","author":"Florent","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/00365548.2011.616221","article-title":"Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria","volume":"44","author":"Dinh","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0035","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1128\/AAC.47.9.2850-2858.2003","article-title":"Biological costs and mechanisms of fosfomycin resistance in Escherichia coli","volume":"47","author":"Nilsson","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0040","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/527442","article-title":"Fosfomycin: use beyond urinary tract and gastrointestinal infections","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0045","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1097\/CCM.0b013e318180fe62","article-title":"Antibiotic resistance\u2014what's dosing got to do with it?","volume":"36","author":"Roberts","year":"2008","journal-title":"Crit Care Med"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2013.05.018_bib0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000222040","article-title":"Pharmacokinetics of fosfomycin","volume":"23","author":"Kirby","year":"1977","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0055","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/jac\/dkh443","article-title":"Impact of plasma protein binding on antimicrobial activity using time-killing curves","volume":"54","author":"Zeitlinger","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0060","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/00003495-199753040-00007","article-title":"Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections","volume":"53","author":"Patel","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000239140","article-title":"Pharmacokinetic profile of fosfomycin trometamol","volume":"39","author":"Bergan","year":"1993","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0070","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/jac\/dkh158","article-title":"Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis","volume":"53","author":"Pfausler","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0075","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ijantimicag.2012.02.010","article-title":"What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance","volume":"39","author":"Udy","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0080","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/0310057X1103900602","article-title":"Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story","volume":"39","author":"Lipman","year":"2011","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1473-3099(01)00093-7","article-title":"Immunotherapy of sepsis","volume":"1","author":"van der Poll","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0090","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.01708-10","article-title":"Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens","volume":"55","author":"Roberts","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0095","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkq070","article-title":"Extracellular concentrations of fosfomycin in lung tissue of septic patients","volume":"65","author":"Matzi","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. D","key":"10.1016\/j.ijantimicag.2013.05.018_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/31.suppl_D.1","article-title":"Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans","volume":"31","author":"Ryan","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0105","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0110","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1128\/AAC.06449-11","article-title":"High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis","volume":"56","author":"Mir\u00f3","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0115","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/jac\/dkg187","article-title":"Target site penetration of fosfomycin in critically ill patients","volume":"51","author":"Joukhadar","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jac\/dkp139","article-title":"Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution","volume":"64","author":"Roberts","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0125","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/CCM.0b013e3181968e44","article-title":"Piperacillin penetration into tissue of critically ill patients with sepsis\u2014bolus versus continuous administration?","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0130","first-page":"171","article-title":"Pharmacokinetic aspects of cerebrospinal fluid penetration of fosfomycin","volume":"5","author":"Pfeifer","year":"1985","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0135","series-title":"New trends in urinary tract infections","first-page":"224","article-title":"In vitro study of fosfomycin trometamol","author":"Reeves","year":"1988"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0140","series-title":"New trends in urinary tract infections","first-page":"121","article-title":"Microbiological studies of fosfomycin trometamol against urinary isolates in vitro","author":"Lerner","year":"1987"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0145","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/jac\/dkl315","article-title":"Mutators among CTX-M \u03b2-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance","volume":"58","author":"Ellington","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum \u03b2-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0155","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/jac\/dks319","article-title":"Prevalence of acquired fosfomycin resistance among extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3","volume":"67","author":"Lee","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0160","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/jac\/dks270","article-title":"Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases","volume":"67","author":"Karageorgopoulos","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.018_bib0165","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/jac\/dkl251","article-title":"Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration","volume":"58","author":"Gattringer","year":"2006","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913002094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913002094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T20:08:51Z","timestamp":1563480531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857913002094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0924857913002094"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.05.018","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}